Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin for Chemotherapy Toxicity in Breast Cancer
NCT05595109Phase 3Unknown
- Sponsor
- Tanta University
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of silymarin in chemotherapy-induced cardiotoxicity (CIC), Toxic liver disease, chemotherapy-induced peripheral neuropathy (CIPN), cognitive impairment, sponsored by Tanta University. Status: unknown.
02
Drugs
silymarin
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)Toxic liver diseasechemotherapy-induced peripheral neuropathy (CIPN)cognitive impairment
Beyond the preview
Go deeper on NCT05595109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595109.